依度沙班:一种直接口服抗凝药
本文综述依度沙班用于非瓣膜性房颤患者卒中预防和静脉血栓栓塞症治疗的药理学、药代动力学、药效学、临床疗效、安全性及治疗地位,指出其不劣于华法林,但肌酐清除率≥95 mL/min的房颤患者使用依度沙班卒中发生率高于华法林。
要点
- 依度沙班是第二个获批每日一次给药的直接口服抗凝药。
- 依度沙班不经过细胞色素P-450系统代谢,药物相互作用较少。
- 房颤患者肌酐清除率≥95 mL/min时使用依度沙班卒中率高于华法林。
核心结论
- 依度沙班在静脉血栓栓塞症(抗凝治疗后)管理和许多非瓣膜性房颤患者卒中风险降低方面不劣于华法林。
研究设计与样本
- 综述依度沙班的药理学、药代动力学、药效学、临床疗效、安全性及治疗地位。
主要发现
- ENGAGE AF-TIMI 48和Hokusai-VTE试验结果显示依度沙班不劣于华法林。
- 临床试验中,肌酐清除率≥95 mL/min的房颤患者使用依度沙班卒中发生率高于华法林。
临床怎么用
- 依度沙班可用于非瓣膜性房颤患者卒中预防和静脉血栓栓塞症治疗。
- 使用依度沙班前应评估肌酐清除率,≥95 mL/min的房颤患者需谨慎。
局限性
- 依度沙班的不良反应特征可能限制其在临床实践中的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and place in therapy of edoxaban for prevention of stroke in patients with nonvalvular atrial fibrillation (AF) and treatment of venous thromboembolism (VTE) are reviewed. SUMMARY: Although warfarin has been an established therapy for stroke prevention in AF and VTE, the need for agents with less monitoring requirements, fewer food and drug interactions, and a lower risk of major bleeding led to the development of direct oral anticoagulants (DOACs). Current DOACs work by either directly blocking thrombin (dabigatran) or inhibiting factor Xa (apixaban, edoxaban, and rivaroxaban). Edoxaban is the newest DOAC and only the second Food and Drug Administration-approved anticoagulant for once-daily administration. Unlike apixaban and rivaroxaban, edoxaban does not interact with the cytochrome P-450 system. The results of the ENGAGE AF-TIMI 48 and Hokusai-VTE trials demonstrated edoxaban's noninferiority to warfarin. However, the adverse-effect profile of edoxaban may limit the drug's use in clinical practice; in clinical trials, patients with AF who had a creatinine clearance of ≥95 mL/min had a higher rate of strokes with the use of edoxaban versus warfarin. CONCLUSION: A review of the literature showed that edoxaban, the most recently approved DOAC, is noninferior to warfarin for management of VTE (after parenteral anticoagulant therapy) and for stroke risk reduction in many patients with nonvalvular AF.
引用
- Poulakos M, Walker JN, Baig U, et al. Edoxaban: A direct oral anticoagulant. Am J Health Syst Pharm. 2017. PMID: 28122753. doi:10.2146/ajhp150821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。